Find Clinical Trial

A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis. EYEGUARD-B


← Back
Study Phase

Phase 3

Therapeutic Area

Other

Active substance/
Medical device

GEVOKIZUMAB, S078989

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS078989
Protocol CodeCL3-78989-002
EudraCT Code2012-001125-27
NCT CodeNCT01965145


Documents and links

Results summary READ MORE
Scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility